Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Cefepime

Summary

Persistence. It cannot be excluded that cefepime is persistent, due to the lack of data.

Bioaccumulation. It cannot be excluded that cefepime bioaccumulates, due to the lack of data.

Toxicity. It cannot be excluded that cefepime is toxic, due to the lack of data.

Risk. Risk of environmental impact of cefepime cannot be excluded, due to the lack of environmental toxicity data.

 

Environmental information is missing on fass.se for cefepime (2024-09-11).

 

For antibiotics in general, it is recommended that these pharmaceuticals are used as restrictively as possible without jeopardise the patient's health.

Detailed information

Assessment report

Assessment report for Exblifep (cefepime, enmetazobactam) about cefepim, 25 January 2024, EMA/63929/2024.

"The applicant has submitted a declaration over the use of cefepime in all members states concerned, including historical consumption data. Consumption has decreased over the last four years, despite a slight increase in the population. This supports the conclusion that total environmental exposure is unlikely to increase and that a full ERA procedure is not necessary."

Author: Health and Medical Care Administration, Region Stockholm